NASDAQ:IMMP

Immutep Stock Forecast, Price & News

$3.32

+0.01 (+0.30 %)

(As of 01/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.20

Now: $3.32▼

$3.35

50-Day Range

$1.96

MA: $3.08▼

$5.69

52-Week Range

$0.53

Now: $3.32▼

$7.95

Volume372,741 shs

Average Volume850,782 shs

Market Capitalization$129.48 million

P/E RatioN/A

Dividend YieldN/A

Beta2.23

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Â'eftilagimod alpha' or Â'efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

MarketRank^™

Overall MarketRank^™

1.28 out of 5 stars

Medical Sector

718th out of 1,926 stocks

Pharmaceutical Preparations Industry

364th out of 773 stocks

3.5 Analyst's Opinion

Consensus Rating
Immutep has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, Immutep has a forecasted upside of 141.0% from its current price of $3.32.
Amount of Analyst Coverage
Immutep has only been the subject of 1 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Immutep has received 303 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Immutep has received 228 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Immutep has received 57.06% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Immutep and other stocks. Vote “Outperform” if you believe IMMP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMMP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Immutep does not currently pay a dividend.
Dividend Growth
Immutep does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immutep insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.16% of the stock of Immutep is held by institutions.

0.0 Earnings and Valuation

Price to Book Value per Share Ratio
Immutep has a P/B Ratio of 5.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:IMMP

Previous Symbol

CUSIPN/A

CIK1506184

Webwww.immutep.com

Phone61-2-8315-7003

EmployeesN/A

Debt

Debt-to-Equity Ratio0.26

Current Ratio9.26

Quick Ratio9.26

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.92 million

Price / Sales26.32

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.57 per share

Price / Book5.82

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares39,000,000

Market Cap$129.48 million

Next Earnings DateN/A

OptionableNot Optionable

$3.32

+0.01 (+0.30 %)

(As of 01/21/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive IMMP News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.

Immutep (NASDAQ:IMMP) Frequently Asked Questions

How has Immutep's stock price been impacted by COVID-19 (Coronavirus)?

Immutep's stock was trading at $2.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IMMP stock has increased by 55.9% and is now trading at $3.32.
View which stocks have been most impacted by COVID-19.

Is Immutep a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immutep in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Immutep stock.
View analyst ratings for Immutep or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Immutep?

Wall Street analysts have given Immutep a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immutep wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Immutep's CEO?

1,448 employees have rated Immutep CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Immutep's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What price target have analysts set for IMMP?

2 brokerages have issued 12 month target prices for Immutep's stock. Their forecasts range from $8.00 to $8.00. On average, they expect Immutep's stock price to reach $8.00 in the next year. This suggests a possible upside of 141.0% from the stock's current price.
View analysts' price targets for Immutep or view Wall Street analyst' top-rated stocks.

Are investors shorting Immutep?

Immutep saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 996,400 shares, an increase of 301.5% from the December 15th total of 248,200 shares. Based on an average daily volume of 5,570,000 shares, the short-interest ratio is currently 0.2 days.
View Immutep's Short Interest.

Who are some of Immutep's key competitors?

Some companies that are related to Immutep include Urovant Sciences (UROV), IDEAYA Biosciences (IDYA), RAPT Therapeutics (RAPT), Cogent Biosciences (UMRX), Forte Biosciences (FBRX), XBiotech (XBIT), Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), BioVie (BIVI), Spruce Biosciences (SPRB), Mirum Pharmaceuticals (MIRM), Spero Therapeutics (SPRO), IVERIC bio (ISEE), Bicycle Therapeutics (BCYC) and Amryt Pharma (AMYT).
View all of IMMP's competitors.

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include CHF Solutions (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT).

Who are Immutep's key executives?

Immutep's management team includes the following people:

Mr. Marc Voigt, CEO, CFO, Chief Bus. Officer & Exec. Director (Age 47)
Ms. Deanne Miller, COO, Gen. Counsel & Company Sec. (Age 43)
Dr. Frederic Triebel, Chief Scientific Officer & Chief Medical Officer (Age 65)
Mr. Thomas Robert John Bloomfield, Company Sec.
Mr. Christian Mueller, Director of Clinical Devel. & Regulatory Affairs
Mr. Shengfei Fang, Fin. Director & Assistant Company Sec.

What is Immutep's stock symbol?

Immutep trades on the NASDAQ under the ticker symbol "IMMP."

How do I buy shares of Immutep?

Shares of IMMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immutep's stock price today?

One share of IMMP stock can currently be purchased for approximately $3.32.

How big of a company is Immutep?

Immutep has a market capitalization of $129.48 million and generates $4.92 million in revenue each year.

What is Immutep's official website?

The official website for Immutep is www.immutep.com.

How can I contact Immutep?

Immutep's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The biotechnology company can be reached via phone at 61-2-8315-7003 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here